Vol 54, No 3 (2020)
Letter to the Editors
Published online: 2020-06-04

open access

Page views 9912
Article views/downloads 26526
Get Citation

Connect on Social Media

Connect on Social Media

Does amantadine have a protective effect against COVID-19?

Albert Cortés Borra1
Pubmed: 32495926
Neurol Neurochir Pol 2020;54(3):284-285.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Zhu Na, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8): 727–733.
  2. Rodon J, Noguera-Julian M, Erkizia I, et al. Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia. .
  3. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders. 2020; 42: 102163.
  4. Abreu G, Aguilar M, Covarrubias D, et al. Amantadine as a drug to mitigate the effects of COVID-19. Medical Hypotheses. 2020; 140: 109755.
  5. Tipton P, Wszolek Z. What can Parkinson’s disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2): 204–206.
  6. Cimolai N. Potentially repurposing adamantanes for COVID‐19. Journal of Medical Virology. 2020; 92(6): 531–532.
  7. Smieszek S, Przychodzen B, Polymeropoulos M. “Amantadine disrupts lysosomal gene expression; potential therapy for COVID19”. .